|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0036525,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0246415,
umls-concept:C0282460,
umls-concept:C1332166,
umls-concept:C1516119,
umls-concept:C1522484,
umls-concept:C1704242
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2010-6-18
|
|
pubmed:abstractText |
The combination of sorafenib with chemotherapy is well-tolerated and is associated with encouraging response rates in several malignances. Both docetaxel and cisplatin are active in gastric cancer. A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-10390007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-12068308,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-12181402,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-12360282,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-12727920,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-15466206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-17075117,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-17095207,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-17215530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-17562243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-17664469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-18172173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-18650514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-18676756,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-18852116,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-19153121,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-19171708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-19474385,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-19652055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-20458025,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20458043-9823902
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2947-51
|
|
pubmed:dateRevised |
2011-8-1
|
|
pubmed:meshHeading |
pubmed-meshheading:20458043-Adenocarcinoma,
pubmed-meshheading:20458043-Adult,
pubmed-meshheading:20458043-Aged,
pubmed-meshheading:20458043-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20458043-Benzenesulfonates,
pubmed-meshheading:20458043-Cisplatin,
pubmed-meshheading:20458043-Esophagogastric Junction,
pubmed-meshheading:20458043-Female,
pubmed-meshheading:20458043-Humans,
pubmed-meshheading:20458043-Male,
pubmed-meshheading:20458043-Middle Aged,
pubmed-meshheading:20458043-Neoplasm Metastasis,
pubmed-meshheading:20458043-Pyridines,
pubmed-meshheading:20458043-Stomach Neoplasms,
pubmed-meshheading:20458043-Survival Rate,
pubmed-meshheading:20458043-Taxoids,
pubmed-meshheading:20458043-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
|
|
pubmed:affiliation |
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104-4283, USA. weijing.sun@uphs.upenn.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
